Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti-Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors

NCT02174172 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02174172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02174172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti-Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2014
Completion date
November 25, 2019
Enrollment
158 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancers